Core Viewpoint - The Hong Kong stock market experienced fluctuations this week, with the consumer sector showing strength while technology and pharmaceutical sectors faced declines [1]. Index Performance - The CSI Hong Kong Stock Connect Consumer Theme Index rose by 0.6% [1]. - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index fell by 2.0% [1]. - The Hang Seng Technology Index decreased by 2.8% [1]. - The CSI Hong Kong Stock Connect Internet Index dropped by 3.0% [1]. - The Hang Seng Hong Kong Stock Connect New Economy Index declined by 3.1% [1]. Fund Flows - The Hang Seng Technology ETF (513010) and the Hong Kong Stock Connect Internet ETF (513040) saw inflows of 920 million and 270 million respectively during the week [1]. Valuation Metrics - The rolling price-to-earnings (P/E) ratios for the indices are as follows: - Hang Seng New Economy Index: 24.5x [3]. - Hang Seng Technology Index: 22.9x [3]. - CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index: 31.9x [3]. - CSI Hong Kong Stock Connect Internet Index: 24.6x [3]. - CSI Hong Kong Stock Connect Consumer Theme Index: 17.2x [3]. Historical Performance - Year-to-date performance shows: - Hang Seng New Economy Index: +29.0% [8]. - Hang Seng Technology Index: +22.6% [8]. - CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index: +68.8% [8]. - CSI Hong Kong Stock Connect Internet Index: +28.2% [8]. - CSI Hong Kong Stock Connect Consumer Theme Index: +23.9% [8]. Sector Composition - The Hang Seng Technology Index consists of the largest 30 stocks related to technology, with over 90% from information technology and consumer discretionary sectors [6]. - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index includes 50 liquid and large-cap stocks from the healthcare sector, with over 90% weight in healthcare [6]. - The CSI Hong Kong Stock Connect Internet Index comprises 30 leading internet companies, primarily from information technology and consumer discretionary sectors [6]. - The CSI Hong Kong Stock Connect Consumer Theme Index includes 50 liquid and large-cap consumer stocks, with over 55% from consumer discretionary [6].

Group 1 - The Hong Kong stock market experienced fluctuations today, with a slight recovery in the afternoon, led by gains in the pharmaceutical, energy, and banking sectors, while technology stocks saw minor declines [1] - The CSI Hong Kong Stock Connect Pharmaceutical and Health Index rose by 0.5%, while the CSI Hong Kong Stock Connect Consumer Theme Index fell by 0.4%, the Hang Seng Hong Kong Stock Connect New Economy Index decreased by 0.6%, the Hang Seng Technology Index dropped by 0.7%, and the CSI Hong Kong Stock Connect Internet Index declined by 1.1% [1] - According to Wind data, as of yesterday, the net inflow of funds into the Hang Seng Technology ETP managed by Yi Fangda (513010) exceeded 2 billion yuan for the month, ranking among the top in its category [1] Group 2 - The Hang Seng New Economy Index tracks the 50 largest stocks within the "new economy" sectors listed under the Hong Kong Stock Connect, primarily including information technology, consumer discretionary, and healthcare [3] - The index decreased by 0.6% today, with a rolling price-to-earnings ratio of 24.6 times [3] - The Hang Seng Technology ETF tracks the Hang Seng Technology Index, which consists of the 30 largest stocks highly related to technology themes, with over 90% of the index comprising information technology and consumer discretionary sectors [4] - The index fell by 0.7% today, with a rolling price-to-earnings ratio of 23.0 times [4] Group 3 - The Hong Kong Stock Connect Pharmaceutical ETF tracks the CSI Hong Kong Stock Connect Pharmaceutical and Health Index, which is composed of 50 highly liquid and large-cap stocks in the healthcare sector, accounting for over 90% of the index [6] - The index rose by 0.5% today, with a rolling price-to-earnings ratio of 31.8 times [6] - The Hong Kong Stock Connect Internet ETF tracks the CSI Hong Kong Stock Connect Internet Index, which has seen a decline of 1.1% today, with a rolling price-to-earnings ratio of 24.8 times [8]

Group 1 - The Hong Kong stock market experienced a rebound in the afternoon, with significant gains in the AI industry chain and new consumption stocks, as evidenced by various indices rising, including the CSI Hong Kong Stock Connect Consumption Theme Index by 1.3% and the CSI Hong Kong Stock Connect Internet Index by 1.2% [1] - Since December, the total inflow into ETFs related to the Hang Seng Technology Index has exceeded 8 billion yuan, with the E Fund Hang Seng Technology ETF (513010) alone attracting over 2 billion yuan, ranking among the top in its category [1] Group 2 - The Hang Seng New Economy ETF (513320) tracks the Hang Seng Stock Connect New Economy Index, which consists of the 50 largest stocks in the "new economy" sector, primarily including information technology, consumer discretionary, and healthcare, with a rolling P/E ratio of 24.3 times and a valuation percentile of 51.2% since its inception in 2018 [2] - The E Fund Hang Seng Technology ETF (513010) tracks the Hang Seng Technology Index, composed of the 30 largest stocks highly related to technology themes, with over 90% of its composition from information technology and consumer discretionary sectors, showing a rolling P/E ratio of 22.7 times and a valuation percentile of 28.4% since its launch in 2020 [2] - The Hong Kong Stock Connect Medical ETF (513200) tracks the CSI Hong Kong Stock Connect Medical and Health Comprehensive Index, consisting of 50 liquid and large-cap stocks in the healthcare sector, which accounts for over 90% of the index, with a rolling P/E ratio of 31.6 times and a valuation percentile of 49.9% since its inception in 2017 [2] - The Hong Kong Stock Connect Internet ETF (513040) tracks the CSI Hong Kong Stock Connect Internet Index, made up of 30 leading internet companies, primarily in information technology and consumer discretionary, with a rolling P/E ratio of 24.5 times and a valuation percentile of 25.2% since its launch in 2021 [2] Group 3 - The E Fund Hong Kong Consumption ETF (513070) tracks the CSI Hong Kong Stock Connect Consumption Theme Index, which includes 50 liquid and large-cap consumption stocks, with nearly 60% in consumer discretionary, showing a rise of 1.3% and a rolling P/E ratio of 17.2 times since its launch in 2020 [3]

Market Performance - The Hong Kong stock market saw a rise in the afternoon, with sectors such as semiconductors, hardware equipment, and pharmaceuticals leading the gains [1] - The CSI Hong Kong Stock Connect Healthcare Index increased by 2.3%, the Hang Seng Stock Connect New Economy Index rose by 1.7%, the Hang Seng Technology Index went up by 1.5%, and the CSI Hong Kong Stock Connect Internet Index gained 1.2% [1] - The CSI Hong Kong Stock Connect Consumer Theme Index experienced a slight decline of 0.1% [1] Fund Inflows - According to Wind data, the Hang Seng Technology ETF (513010) and the Hong Kong Stock Connect Internet ETF (513040) saw net inflows of 620 million yuan and 190 million yuan, respectively, over the past week [1] Strategic Insights - CITIC Securities highlighted that the "14th Five-Year Plan" emphasizes the construction of a modern industrial system and accelerating high-level technological self-reliance, which may lead to new policy support for strategic emerging industries such as new energy, new materials, aerospace, and quantum technology [1] - Looking ahead to 2026, the Hong Kong stock market is expected to benefit from the internal catalysts of the "14th Five-Year Plan," with recommendations for investors to focus on investment opportunities in AI-related sectors and consumer electronics [1]

Core Insights - The domestic index investment market has rapidly expanded, with the total scale of non-monetary ETFs and other index funds nearing 8 trillion yuan by the end of Q3 2023, marking a growth of 2.1 trillion yuan within the year [1] - E Fund has emerged as a leader in the industry, with its public index products surpassing 1 trillion yuan in scale [1] Tracking Error Control - Precise control of tracking error is essential for index investment, reflecting the fund company's expertise [2] - Tracking error primarily arises from stock position deviations and individual stock weight discrepancies, necessitating careful management of stock positions and cash reserves [2] - E Fund's A-share ETFs have a scale-weighted tracking error of 0.14%, ranking among the top in the industry [2] Generating Excess Returns - Beyond tracking error control, creating excess returns through refined management is crucial for enhancing investor experience [3] - Cost reduction strategies include minimizing management, custody, and trading costs, while exploring diverse strategies for sustainable return enhancement [3] - Liquidity compensation strategies, such as block trades and inquiry transfers, can effectively lower overall holding costs and stabilize excess returns [3] Full-Cycle Management - The professional nature of index products extends throughout their entire lifecycle, from issuance to ongoing management [6] - E Fund has established a standardized full-process management mechanism to ensure stable operations across various market conditions [6] - The company's flagship product, the CSI 300 ETF, has operated smoothly for over 12 years without any risk events [6] Platform Empowerment - The enhancement of index business professionalism relies on systematic support from investment research, trading, and IT platforms [7] - E Fund has developed an advanced index investment management platform that integrates extensive management experience into a quantifiable and replicable system [7] - This platform ensures accurate investment instructions and provides comprehensive feedback on trading execution and portfolio management [7] Active Research Team Collaboration - E Fund's active research team provides a solid foundation for designing industry and thematic index products, leveraging their experience in fundamental pricing and risk management [8] - The collaboration between the index and active teams enhances professional capabilities, contributing to the company's leading position in the industry [8] - As the index investment market reaches a new scale of 8 trillion yuan, the focus is shifting from growth to quality enhancement, with professional capabilities becoming a core competitive advantage [8]

Core Insights - The article discusses the recent financial performance of a leading company in the technology sector, highlighting significant revenue growth and strategic initiatives aimed at expanding market share [4] Group 1: Financial Performance - The company reported a revenue increase of 25% year-over-year, reaching $5 billion in the last quarter [4] - Net profit rose to $1 billion, reflecting a 30% increase compared to the same period last year [4] - The gross margin improved to 45%, up from 40% in the previous year, indicating better cost management and pricing strategies [4] Group 2: Strategic Initiatives - The company announced plans to invest $500 million in research and development over the next three years to enhance product innovation [4] - A new partnership with a leading cloud service provider was established to expand service offerings and improve customer reach [4] - The company aims to enter emerging markets, targeting a 15% increase in international sales by the end of the next fiscal year [4]

Core Insights - The Hong Kong stock market showed mixed performance this week, with significant rebounds in the pharmaceutical sector and active performance in the new consumption sector, while popular technology stocks experienced varied movements [1] - The CSI Hong Kong Stock Connect Pharmaceutical and Health Index rose by 6.9%, and the CSI Hong Kong Stock Connect Consumption Theme Index increased by 2.3%, while the Hang Seng Technology Index fell by 0.4% [1][3] Index Performance - The Hang Seng New Economy Index increased by 0.7%, while the Hang Seng Technology Index decreased by 0.4% [3] - The rolling price-to-earnings (P/E) ratios for the indices are as follows: Hang Seng New Economy Index at 24.7x, Hang Seng Technology Index at 23.1x, CSI Hong Kong Stock Connect Pharmaceutical and Health Index at 29.2x, CSI Hong Kong Stock Connect Internet Index at 24.2x, and CSI Hong Kong Stock Connect Consumption Theme Index at 21.6x [3] - The rolling P/E ratio percentiles indicate that the Hang Seng New Economy Index is at 54.1%, the Hang Seng Technology Index at 30.8%, the CSI Hong Kong Stock Connect Pharmaceutical and Health Index at 46.0%, the CSI Hong Kong Stock Connect Internet Index at 23.0%, and the CSI Hong Kong Stock Connect Consumption Theme Index at 21.4% [3] Market Outlook - Western Securities noted that the reopening of the U.S. government and the resumption of spending by the Treasury could lead to a loosening of dollar liquidity, potentially driving a rebound in the Hong Kong stock market, with the Hang Seng Technology Index expected to benefit from a new round of strong rebound [1]

Core Viewpoint - The Hong Kong pharmaceutical sector showed strong performance in the morning session, with various indices reflecting significant gains, indicating a positive market sentiment towards innovative drug companies and the broader healthcare industry [1]. Group 1: Index Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 4.3% [1]. - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index increased by 3.3% [1]. - The CSI Innovative Drug Industry Index saw a rise of 1.9% [1]. - The CSI Biotechnology Theme Index grew by 1.4% [1]. - The CSI 300 Pharmaceutical and Health Index climbed by 1.3% [1]. Group 2: Fund Inflows - The Hang Seng Innovative Drug ETF (159316) attracted a total of 1.4 billion yuan in inflows over the past month [1]. Group 3: Index Valuation Metrics - The rolling price-to-earnings (P/E) ratio for the CSI Biotechnology Theme Index is currently at 58.0 times, with a valuation percentile of 70.7% since its inception in 2015 [5]. - The rolling P/E ratio for the CSI 300 Pharmaceutical and Health Index stands at 31.3 times, with a valuation percentile of 49.3% since its inception in 2007 [7].

Core Viewpoint - The Hong Kong Stock Connect Pharmaceutical ETF (513200) experienced a decline of 1.97% on November 7, with a trading volume of 191 million yuan, indicating a downward trend in the pharmaceutical sector [1] Group 1: Fund Performance - The ETF's total shares increased by 4 million, bringing the latest total to 1.813 billion shares, with a notable increase of 38 million shares over the past 20 trading days [1] - The latest net asset value of the ETF is calculated at 2.057 billion yuan [1] - Since its inception on January 19, 2022, the ETF has returned 13.45%, while its return over the past month has been -13.15% [1] Group 2: Management and Benchmark - The ETF is managed by E Fund Management Co., Ltd., with Wu Chendong as the fund manager [1] - The performance benchmark for the ETF is the CSI Hong Kong Stock Connect Pharmaceutical and Healthcare Composite Index return rate, adjusted using the valuation exchange rate [1]

Group 1 - The pharmaceutical sector is experiencing a rebound with strong capital allocation intentions, as evidenced by the medical ETF (512010) receiving a net inflow of 400 million yuan over four consecutive trading days, and the Hang Seng Innovation Drug ETF (159316) attracting over 1.6 billion yuan in the past month [1] - The pharmaceutical and biotechnology sector reported a year-on-year net profit growth of 7.7% in Q3 2025, with a gross margin maintained at 31.4%, showing a clear trend of improvement [1] - Innovative drugs are leading the industry, with several companies achieving high growth in performance due to the commercialization of innovative drugs and the confirmation of upfront payments for business development overseas [1] Group 2 - Analysts believe that the pharmaceutical sector is poised for a valuation recovery in Q4, driven by multiple catalysts including performance recovery and policy support, alongside a loose overseas liquidity environment [1] - The medical ETF (512010) tracks the CSI 300 Healthcare Index, reflecting the overall performance of leading pharmaceutical stocks in the A-share market, while the Hang Seng Innovation Drug ETF (159316) focuses exclusively on innovative drug companies in the Hong Kong stock market [1] - Other related ETFs managed by E Fund include the E Fund Innovation Drug ETF (516080) and the Hong Kong Stock Connect Medical ETF (513200), providing investors with diverse options to invest in leading pharmaceutical companies in both A and H shares [1]